Upgrade to SI Premium - Free Trial

Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'

May 21, 2026 9:00 AM
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $40.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments